{"id":120012,"date":"2026-08-24T23:37:30","date_gmt":"2026-08-24T23:37:30","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/120012\/"},"modified":"2026-08-24T23:37:30","modified_gmt":"2026-08-24T23:37:30","slug":"roche-licenses-hanmi-obesity-drug-for-up-to-2-3b","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/120012\/","title":{"rendered":"Roche licenses Hanmi obesity drug for up to $2.3B"},"content":{"rendered":"<p data-pm-slice=\"1 1 []\">Why it matters: The agreement adds another mechanism to Roche\u2019s growing obesity pipeline as drugmakers look beyond weight loss alone and focus on preserving muscle.<\/p>\n<p>How it works: HM17321 is a long-acting analog of urocortin-2, or UCN2, a signaling protein involved in metabolic and cardiovascular processes. Unlike GLP-1 drugs, the peptide uses a non-incretin mechanism. Hanmi designed it to reduce fat while preserving lean body mass \u2013 a concern with existing obesity treatments \u2013 and sees potential for its use alone or alongside GLP-1 therapies.<\/p>\n<p><a href=\"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/2579-P\/167660\/2579-P-Temporal-Mechanistic-Shifts-Underlying\" rel=\"nofollow noopener\" target=\"_blank\">Preclinical studies<\/a> linked HM17321 to weight reduction as both a monotherapy and in combination with GLP-1 drugs, according to Hanmi.<\/p>\n<p>Zoom in: The U.S. Food and Drug Administration cleared Hanmi\u2019s investigational new drug application in November 2025. An ongoing Phase 1 trial is assessing safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and people with obesity. Hanmi will complete that study before Genentech takes control of development from Phase 2.<\/p>\n<p>Roche also plans to explore the candidate in conditions associated with obesity, including type 2 diabetes and cardiovascular disease.<\/p>\n<p>Big picture: Last year, Roche unveiled its plan to become a top-three company in obesity. Its pipeline already includes the injectable GLP-1\/GIP drug enicepatide, oral GLP-1 candidate CT-996 and petrelintide, an amylin analog partnered with Denmark\u2019s Zealand Pharma.<\/p>\n<p>The Swiss group is also testing the muscle-building antibody emugrobart with Eli Lilly\u2019s Mounjaro in Phase 2. HM17321 gives Roche a second way to tackle the loss of lean mass associated with weight reduction.<\/p>\n","protected":false},"excerpt":{"rendered":"Why it matters: The agreement adds another mechanism to Roche\u2019s growing obesity pipeline as drugmakers look beyond weight&hellip;\n","protected":false},"author":2,"featured_media":120013,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[14272,134],"class_list":["post-120012","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-licensing","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117153119901664725","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/120012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=120012"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/120012\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/120013"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=120012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=120012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=120012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}